Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Thoratec Announces Presentations at Upcoming Investor Conferences

November 7, 2011

PLEASANTON, Calif., Nov. 7, 2011 /PRNewswire/ — Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences.

On Wednesday, November 9, the company will participate in the Credit Suisse 2011 Healthcare Conference. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 9 a.m., Mountain Standard Time (11 a.m., Eastern Standard Time). The presentation will be available through the conference web site at http://cc.talkpoint.com/cred001/110911a_ah/?entity=10_RELXBWQ or on the company’s website at http://www.thoratec.com.

On Wednesday, November 16, Thoratec will participate in the Lazard Capital Markets 8th Annual Healthcare Conference. The presentation by Gary F. Burbach will begin at 9 a.m., Eastern Standard Time (6 a.m., Pacific Standard Time). The presentation will be available through the conference web site at http://wsw.com/webcast/lz11/thor/ or on the company’s web site at http://www.thoratec.com.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company’s products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

SOURCE Thoratec Corporation


Source: PR Newswire